SEMA3B Loss Disrupts AMPK-Associated Mitochondrial Homeostasis and Aggravates Cardiac Injury

The human heart is a relentless engine, beating roughly one hundred thousand times a day to pump blood through the body. To keep this rhythm going, heart muscle cells rely on tiny power plants called mitochondria. These organelles do more than just generate energy; they also manage the cell's internal chemistry, handle waste, and decide when a cell should live or die. When these power plants malfunction, the heart struggles to function, leading to conditions like heart failure or damage after a heart attack. Scientists have long known that keeping mitochondria healthy is vital, but the specific signals that tell them to stay in good working order are not fully understood. One such signal might come from a protein called Semaphorin 3B. Originally discovered as a guide for nerve cells growing in the developing brain, this protein has recently been found in fat tissue surrounding the heart, suggesting it might play a role in heart health too. Researchers wanted to know if this protein helps the heart's power plants run smoothly and what happens when it is missing.

A team of scientists set out to investigate the relationship between Semaphorin 3B and the heart's energy management system. They focused on a specific pathway inside cells known as AMPK, which acts like a master switch for metabolism. When a cell senses it needs more energy, this switch flips on, telling the mitochondria to work harder, clean themselves up, and produce more fuel. The researchers wondered if Semaphorin 3B was needed to keep this switch active. To find the answer, they worked with two groups: human heart muscle cells grown in a laboratory dish and mice fed a high-fat diet to stress their cardiovascular systems. In both groups, the scientists used a precise tool to silence the gene that makes Semaphorin 3B, effectively turning the protein off to see what would happen. They then compared these groups to others where the protein was still present, and to a third set where they tried to fix the problem by giving the mice a drug that activates the AMPK switch directly.

When the researchers removed Semaphorin 3B from the human heart cells, the results were immediate and troubling. The master metabolic switch, AMPK, stopped working as well as it should. Without this signal, the cells began to lose their energy reserves. The mitochondria, which usually maintain a strong electrical charge to power the cell, started to leak energy and become less efficient. The cells produced less of the fuel molecule ATP, which is essential for contraction, and their overall metabolic activity slowed down. At the same time, the cells began to accumulate harmful waste products, specifically reactive oxygen species, which are like rust that damages the cell from the inside. The balance of fats in the cells also shifted toward a more dangerous profile, with higher levels of bad cholesterol and lower levels of good cholesterol. The cells also showed signs of inflammation, releasing chemical signals that usually attract immune cells to a site of injury.

The situation was even more severe in the mice. Those with reduced levels of Semaphorin 3B developed visible damage to their heart tissue. Under a microscope, the heart muscle showed signs of necrosis, where cells had died and broken down, and there was a significant increase in scar tissue forming between the muscle fibers. This scarring, known as fibrosis, makes the heart stiff and less able to pump blood effectively. The mice also suffered from higher rates of cell death, or apoptosis, in their heart tissue. Their blood tests revealed a lipid profile that was worse than normal, with elevated triglycerides and cholesterol, mirroring the unhealthy changes seen in the human cells. The loss of Semaphorin 3B had essentially left the heart vulnerable to metabolic stress, causing its power plants to fail and its structure to deteriorate.

However, the story did not end with damage. The researchers introduced a drug called AICAR, which is known to activate the AMPK switch, to see if it could rescue the failing cells. In the human heart cells where Semaphorin 3B had been silenced, adding AICAR reversed most of the damage. The metabolic switch was turned back on, the mitochondria regained their electrical charge, and the cells began producing energy again. The harmful buildup of waste products decreased, and the cells returned to a healthier state. In the mice, the treatment was equally effective. The drug reduced the amount of dead heart tissue and prevented the formation of new scar tissue. It also improved the lipid profile in their blood, lowering the dangerous fats and raising the protective ones. The drug appeared to counteract the effects of the missing protein, though the researchers noted that AICAR can influence other cellular processes beyond just AMPK, so this rescue does not prove a direct interaction between Semaphorin 3B and AMPK or confirm that AMPK is the sole target.

These findings suggest that Semaphorin 3B plays a crucial role in maintaining the health of the heart by supporting the AMPK pathway. When this protein is present, it helps ensure that the heart's power plants are efficient, clean, and capable of generating the energy needed for the heart to beat. When it is missing, the heart loses this protection, leading to a cascade of failures that result in structural damage and metabolic imbalance. The fact that activating AMPK with a drug could fix these problems indicates that the two are linked in a signaling pathway, although the exact molecular steps connecting them remain unknown. The researchers propose that Semaphorin 3B might be a guardian of heart health, working behind the scenes to keep the energy systems running smoothly. While the study does not yet prove exactly how Semaphorin 3B talks to the AMPK switch, or which specific receptors are involved, the evidence is strong that losing this protein puts the heart at risk.

The study also highlights the complexity of heart disease. It shows that the problem is not just about blocked arteries or high blood pressure, but also about the tiny molecular signals that keep heart cells alive and functioning. By identifying Semaphorin 3B as a key player, the researchers have opened a new door for understanding how the heart manages its energy. The ability to rescue the heart from damage by turning on the AMPK switch suggests a potential future strategy for treatment, though much more work is needed to confirm these findings in humans. For now, the research provides a clear picture of what happens when a specific protective protein is lost: the heart's internal power grid collapses, leading to injury. Restoring the signal that keeps that grid online could be a powerful way to protect the heart from the wear and tear of disease and aging.